Exton-based Frontage Laboratories and Frontage Canada, its wholly-owned subsidiary, recently completed their purchase of Toronto-based Nucro-Technics and its affiliate Nucro-Technics Holdings.
Nucro-Technics, a pharmaceutical contract research organization, conducts analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services. It provides consulting services in quality control and assurance, and in Natural Health Product Regulations.
The company operates in a 60,000-square-foot facility in the Toronto metropolitan area. Employees test large and small molecules designed to treat various medical conditions.
“This acquisition not only significantly strengthens our presence in Canada, but also will enable the combined organization to offer a more expansive suite of services to clients across the globe,” Dr. Abdul Mutlib, Frontage CEO, said. We are looking forward to partnering with the Nucro team to deliver the world-class expertise that clients have come to expect from us.”
Nucro-Technics has been conducting studies for more than 50 years on behalf of clients and has developed and validated numerous methods. Clients include biotech, pharmaceutical and medical device companies, and industry trade groups and academia. Studies are in compliance with industry regulations.
Frontage Holdings Corp. is a global contract research organization providing product development services from drug discovery to the late phase clinical process.